Citius Oncology, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price
Citius Oncology, Inc. (CTOR) had Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price of $0.80 per share as of 2025-09-30, per its 10-K filed 2025-12-23.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice · last filed 2025-12-23
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price $0.80.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price |
|---|---|
| 2025-09-30 | $0.80 10-K · filed 2025-12-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |